Diabetes prevalence among Americans may increase to 33%, CDC study finds
ATLANTA The rate of diabetes among Americans is on an upswing and likely will reach epic proportions by 2050, costing the government millions.
Anew study by the Centers for Disease Control and Prevention and published in Population Health Metrics found that annual diagnosed diabetes incidence (new cases) will increase from about eight cases per 1,000 people in 2008 to about 15 in 2050. The authors also projected that — assuming low incidence and relatively high diabetes mortality — total diabetes prevalence (diagnosed and undiagnosed cases) is projected to increase from 14% in 2010 to 21% of the U.S. adult population by 2050, but noted that if recent increases in diabetes incidence continue and diabetes mortality is relatively low, prevalence will increase to 33% by 2050.
In 2007, diabetes cost the United States in excess of $174 billion. With the increased prevalence of diabetes in the country, the CDC suggested that the projected loss in quality of life and the projected costs of providing health care could be significant, as the healthcare costs of a person with diagnosed diabetes are approximately 2.3 times higher than nondiabetics, the authors noted.
"These are alarming numbers that show how critical it is to change the course of Type 2 diabetes," said Ann Albright, director of CDC’s division of diabetes translation. "Successful programs to improve lifestyle choices on healthy eating and physical activity must be made more widely available, because the stakes are too high and the personal toll too devastating to fail."
The authors also noted that intervention can reduce, but not eliminate, increases in diabetes prevalence.
Transcript Pharmacy receives ACHC accreditation
JACKSON, Miss. A pharmacy that specializes in serving patients with chronic medical conditions has received accreditation status from the Accreditation Commission for Health Care for specialty pharmacy services.
Transcript Pharmacy said Wednesday it was awarded ACHC accreditation, a voluntary activity where healthcare organizations submit to peer review of their internal policies, processes and patient care delivery against national standards. Transcript recently was involved in a year-long study conducted by Virginia Commonwealth University, which showed that through personalized communication with each patient, Transcript improved compliance.
“This recognition demonstrates that the level of care and quality of services we offer bring significant benefits to the patients that we serve,” said company president Cliff Osbon.
K-V establishes generic drug subsidiary Nesher Pharmaceuticals
ST. LOUIS K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said Wednesday.
K-V announced the establishment of Nesher Pharmaceuticals, appointing as its president Mark Hartman, who has had several positions in generic drug companies.
“Mark brings recognized depth and breadth of generic industry experience and leadership to K-V,” K-V interim president and CEO Greg Divis said. “We are excited to have Mark join our organization and look forward to him leading the introduction of Nesher Pharmaceuticals Inc., K-V’s new generic subsidiary.”